Adrenaline

CLINICAL USE

Sympathomimetic and inotropic agent

DOSE IN NORMAL RENAL FUNCTION

1–20 micrograms/minute

PHARMACOKINETICS

Molecular weight :
183.2

%Protein binding :
50

%Excreted unchanged in urine :
1

Volume of distribution (L/kg) :
No data

half-life – normal/ESRD (hrs) :
Phase 1: 3 minutes;
Phase 2: 10 minutes

DOSE IN RENAL IMPAIRMENT

GFR (mL/MIN)

20 to 50 : Dose as in normal renal function

10 to 20 : Dose as in normal renal function

<10 :
Dose as in normal renal function

DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES

CAPD :
Not dialysed. Dose as in normal renal function

HD :
Not dialysed. Dose as in normal renal function

HDF/high flux :
Unknown dialysability. Dose as in
normal renal function

CAV/VVHD :
Not dialysed. Dose as in normal renal function

IMPORTANT DRUG INTERACTIONS

Potentially hazardous interactions with other drugs

Alpha-blockers: avoid with tolazoline

Anaesthetics: increased risk ofarrhythmias if given with volatile
anaesthetics

Antidepressants: increased risk ofarrhythmias and hypertension if given
with tricyclics; MAOIs and moclobemide
may cause hypertensive crisis.

Beta-blockers: increased risk of severehypertension

Clonidine: possible increased risk ofhypertension
Dopaminergics: effects possibly increased

by entacapone; avoid concomitant use
with rasagiline

Sympathomimetics: effects possiblyenhanced by dopexamine

ADMINISTRATION

Reconstition

1 mg in 100 mL glucose 5%

6 mL/hour = 1 microgram/minute –according to local protocol

Route

IV, IM, SC

Rate of Administration

Monitor blood pressure and adjust dose

according to response

Comments

–

OTHER INFORMATION

Catecholamines have a high non-renal

systemic clearance; therefore the effect of
any renal replacement therapy is unlikely
to be relevant

Tags: post-by-auto-php